Heart failure with preserved ejection fraction (HFpEF) is increasingly common but its pathogenesis is poorly understood. The ability to assess genetic and pharmacologic interventions is hampered by ...
LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results